Why Radius Health Stock Is Exploding Higher Today

Shares of Radius Health (NASDAQ: RDUS), a biopharmaceutical company, are soaring today in response to positive clinical-trial data. Investors excited about elacestrant, an experimental new cancer treatment Radius Health is developing in partnership with the Menarini Group, an Italian company, pushed the stock up 48.8% shortly after the market opened. The stock was still up 34.6% as of 11:25 a.m. EDT on Wednesday.

Elacestrant is an experimental therapy for breast cancer patients who have tumors that express lots of estrogen receptors but lack receptors for human epidermal growth factor. In the phase 3 Emerald trial with ER+/HER- patients, treatment with elacestrant significantly reduced the risk of death or worsening disease.

Image source: Getty Images.

Source Fool.com